BioLineRx Ltd. (NASDAQ:BLRX) Q1 2023 Earnings Conference Call May 24, 2023 10:00 AM ET

Company Participants

John Lacey - Investor Relations

Philip Serlin - Chief Executive Officer

Mali Zeevi - Chief Financial Officer

Holly May - Chief Commercial Officer

Ella Sorani - Chief Development Officer

Tami Rachmilewitz - Chief Medical Officer

Conference Call Participants

Joe Pantginis - H.C. Wainwright

Mark Breidenbach - Oppenheimer

John Vandermosten - Zacks

Operator

Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx First Quarter 2023 Financial Results Conference Call. [Operator Instructions]

I'd now like to turn over the call to John Lacey, Head of Investor Relations and Corporate Communications BioLineRx. Please go ahead.

John Lacey

Thank you, operator. Before turning the call over to management, I would like to make the following remarks concerning forward-looking statements. All statements in this conference call, other than historical facts, are indeed forward-looking statements. The words anticipate, believe, estimate, expect, intend, guidance, confidence, target, project and other similar expressions are used typically to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and may involve and are subject to certain risks and uncertainties and other factors that may affect BioLineRx's business, financial condition and other operating results. These include but are not limited to, the risk factors and other qualifications contained in BioLineRx's annual report on Form 20-F, quarterly reports filed in a 6-K and other reports filed by BioLineRx with the SEC to which your attention is directed. Actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements. BioLineRx expressly disclaims any intent or obligation to update these forward-looking statements.

At this time, it is now my pleasure to turn the call over to Phil Serlin, Chief Executive Officer of BioLineRx.

Philip Serlin

Thank you, John and good morning, everyone. Thank you for joining us on our first quarter 2023 results conference call today. Earlier this morning, we issued a press release, a copy of which is available in the Investor Relations section of our website. It was also filed as a 6K.

As is our practice, I will begin with an overview. Then Mali Zeevi, our Chief Financial Officer, will provide a discussion of our financial results. We will then open the call and are looking forward to your questions. Also joining the call for Q&A are Ella Sorani, our Chief Development Officer, Holly May, President of BioLineRx USA, and Tami Rachmilewitz, MD, our Chief Medical Officer.